SMAD3 and osteosarcoma: Here, we demonstrated that the ability of halofuginone to inhibit the TGF-β/Smad3 cascade in osteosarcoma reduces the expression and activity of MMP-2, a protein highly implicated in the migration and invasion processes [11, 33, 34].